Ernexa Therapeutics Inc. (ERNA) EBT Margin (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly EBT Margin came in at 204110.53% in Q4 2024, up 21667583.0% YoY from N/an in Q1 2024, and up 3838.03% on a QoQ basis from 5460.37% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) EBT Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 13 years of EBT Margin data on file, last reported at 204110.53% in Q4 2024.
- Quarterly EBT Margin rose 21667583.0% year-over-year to 204110.53% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3.33% (up 2167433.0% YoY) and the FY2024 annual result came in at 3.33%, up 2167433.0% from the prior year.
- EBT Margin climbed to 204110.53% in Q4 2024, from 5460.37% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 204110.53% in Q4 2024 to a low of 14134.04% in Q1 2024.
- A 3-year average of 16607.28% and a median of 5460.37% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2020 — EBT Margin sank 9431 bps — and 2024, when it soared 21667583 bps.
- Tracing ERNA's EBT Margin over 3 years: stood at 403.83% in 2020, then sank by 3212 bps to 12565.31% in 2023, then soared by 1724 bps to 204110.53% in 2024.
- The last three EBT Margin figures came in at 204110.53% (Q4 2024), 5460.37% (Q3 2024), and 11757.45% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 204,110.53% |
| Sep 30, 2024 | -5,460.37% |
| Jun 30, 2024 | -11,757.45% |
| Mar 31, 2024 | -14,134.04% |
| Dec 31, 2023 | -12,565.31% |
| Sep 30, 2023 | -10,978.43% |
| Dec 31, 2020 | 403.83% |
| Sep 30, 2020 | -101.56% |
| Mar 31, 2020 | -51.67% |
| Dec 31, 2019 | -25.08% |
| Sep 30, 2019 | -7.25% |
| Jun 30, 2019 | -1.72% |
| Mar 31, 2019 | -6.25% |
| Dec 31, 2018 | -0.81% |
| Sep 30, 2018 | 3.86% |
| Jun 30, 2018 | -1.77% |
| Mar 31, 2018 | -7.06% |
| Dec 31, 2017 | -11.22% |
| Sep 30, 2017 | -3.37% |
| Jun 30, 2017 | -2.85% |